PCI Pharma expands its serialization capability
The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.
PCI Pharma Services has announced a significant expansion of its serialization capability across the company's global supply network to support clients in advance of meeting both US DSCSA and EU FMD implementation dates.
The company has been actively serializing commercial products for both domestic and international markets for the past 5 years, with products destined for North America and Europe, in addition to emerging market geographies such as South Korea, Turkey, Brazil, China and others. In total, PCI supports medicines destined to over 100 global countries. The company's expansion triples its global serialization capacity in advance of upcoming DSCSA and FMD requirements.
PCI has partnered with Antares Vision, Marchesini and Domino for this latest installation, utilizing Antares’ leading serialization platform and technology architecture across a variety of serialization technology platforms and applications. The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.
In addition, serialization technologies support ancillary and tertiary packaging, corrugated shippers and palletization solutions for supporting multi-level product aggregation. Aggregation is technically not a requirement for compliance to the 2017 DSCSA deadline, however PCI has strongly supported the advanced use of aggregation to realize significant benefits in packaging operations as well as the broader pharmaceutical supply chain.
Commenting on the expansion, Vice President of Global Engineering, Ken Richardson shared: “Serialization preparedness is the topic on everyone’s mind in the pharmaceutical industry. We are very excited about the next phase of our global serialization initiative and brand security program here at PCI. Having active developed and supported serialization over the past 5 years with numerous commercial applications around the world, we have a significant body of knowledge to share with clients. With these key learnings from practical applications of Serialization and anti-counterfeiting technologies, we have positioned ourselves to support our clients as they start to truly develop their own global Serialization strategies.
“This latest investment is considerable, and features what we believe are truly industry-leading technologies. The spotlight is on the industry to meet the November deadline and PCI has directed an amazing amount of financial resource, technological expertise and manpower to help our clients be prepared.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance